Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Immune checkpoint inhibitor-based treatment was equally effective as a frontline treatment for both Black and White patients with metastatic renal cell carcinoma in separate analyses.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Cancer Statistical Fact Sheets are summaries of common cancer types developed to provide an overview of frequently-requested cancer statistics including incidence, mortality, survival, stage, prevalence,…
In this issue of Blood, Hayashi et al1 assessed the correlation of the level of measurable residual disease (MRD) at the end of induction (EOI) with…
Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Pembrolizumab with chemotherapy led to a positive trend in overall survival among patients with endometrial cancer.
May 22, 2024: Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…